Optimal antituberculosis therapy is essential for favorable
clinical outcomes. Peak plasma concentrations of first-line
antituberculosis drugs in infants with living HIV receiving
WHO-recommended dosing were low compared with refer-
ence values for adults, supporting studies on increased doses of
first-line TB drugs in infants.